Scioderm has joined Amicus Therapeutics in
the fight against Epidermolysis Bullosa.

Scioderm has been acquired by Amicus and will continue to work
to develop Zorblisa™ as the first potential treatment for EB.

Learn more about Amicus

What is EB?

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder that typically manifests at birth or early childhood and for which there are currently no approved treatments.

Learn More go

About Scioderm

Our team is working hard to develop innovative therapies for patients with high need, including those with rare diseases.

Learn More go

Discover How Scioderm is Making a Difference Today.

We recently announced the initiation of a Phase 3 registration trial for our lead therapy, Zorblisa™, a topical therapy for the treatment of blisters and lesions in patients with Epidermolysis Bullosa (EB).

Learn More

Proud Sponsors of: